Abiomed Markets Impella 2.5 Cardiac Assist Device To Cath Labs

Abiomed is targeting its Impella 2.5 cardiac assist device at the top 300 interventional cardiology labs in the United States, firm CEO Michael Minogue said in a June 2 conference call announcing the market launch